ClinicalTrials.gg
RecruitingNCT05908695Updated Nov 9, 2023

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

A Phase 4 interventional study of GV-971 and Placebo in Alzheimer's Disease, sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd.. Recruiting at 50 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,312
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
12th of 176
1,312 · median 100
Started
2023
with 20 others
Phase 4
11 of 260
4 open now
Primary completion
2029-06
later than 135 of 161 live
Registered
113th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 12th largest by planned enrollment of the 176 interventional ones that give a count, is one of 21 that started in 2023, is one of 11 in phase 4, reaches primary completion later than 135 of the 161 other live ones, and was the 113th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate AD per NIA-AA.
  • History of cognitive and functional decline over at least 1 year.
  • scores between 11 and 24 (inclusive) at baseline.
  • Hachinski Ischemic Score (HIS) scale total score ≤ 4.
  • Hamilton Rating Scale for Depression/17 items (HAMD) total score ≤ 10.
  • Brain MRI scan show the highest possibility of AD.
  • Have a reliable study partner/caregiver.
  • Sign the form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a dementia-related central nervous system disease other than AD.
  • Major structural brain disease as judged by MRI.
  • A resting heart rate of \< 50 beats per minute (bpm) after 10 minutes of rest.
  • Major medical illness or unstable medical condition within 12 months of screening.
  • Concomitant use of donepezil, rivastigmine, galanthamine, huperzine A, memantine, or aducanumab within 6 moinths prior to baseline.
  • Inadequate hepatic function.
  • Inadequate organ function.
  • abnormalities.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,312 participants (estimated)

Study arms

  • Experimental
    GV-971

    Drug: GV-971

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugGV-971

    Administered PO

  • DrugPlacebo

    Administered PO

06

What researchers measure

Primary outcomes

  1. Change from baseline in the ADAS-cog/12 score

    Change from baseline in Alzheimer's Disease Assessments Scale - cognitive (ADAS-cog/12) scale total score. The total score of ADAS-cog/12 is 0-75, with higher scores mean a worse outcome.

    Time frame: Baseline, 36 weeks

  2. Change from baseline in ADCS-ADL23 score

    Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living-23-item Scale (ADCS-ADL23) score in moderate AD participants. The total score of ADCS-ADL23 is 0-78, with higher scores mean a better outcome.

    Time frame: Baseline, 36 weeks

Secondary outcomes

  1. Change from baseline in MMSE score

    Change from baseline in Mini-Mental State Examination (MMSE) score. The total score of MMSE is 0-30, with higher scores mean a better outcome.

    Time frame: Baseline, 36 weeks

  2. Change from baseline in the CIBIC-Plus score

    Change from baseline on Clinician's Interview-Based Impression of Change Plus (CIBIC-Plus) scale total score. The total score of CIBIC-Plus is 1-7, with higher scores mean a worse outcome.

    Time frame: Baseline, 36 weeks

  3. Change from baseline in NPI score

    Change from baseline in Neuropsychiatric Inventory (NPI) score. The total score of NPI is 0-144, with higher scores mean a worse outcome.

    Time frame: Baseline, 36 weeks

  4. Change from baseline in ADCS-ADL23 score

    Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living-23-item Scale (ADCS-ADL23) score. The total score of ADCS-ADL23 is 0-78, with higher scores mean a better outcome.

    Time frame: Baseline, 36 weeks

Other outcomes

  1. Change from baseline on A-beta protein of CSF

    Change from baseline on biomarkers of CSF A-beta protein after 36 weeks of treatment.

    Time frame: Baseline, 36 weeks

  2. Change from baseline on Tau protein of CSF

    Change from baseline on biomarkers of CSF Tau protein after 36 weeks of treatment.

    Time frame: Baseline, 36 weeks

  3. Change from baseline on biomarkers of Th1/Th2 cell subtypes

    Change from baseline on biomarkers of peripheral blood immune cell subtypes of Th1/Th2 after 36 weeks of treatment.

    Time frame: Baseline, 36 weeks

07

Study locations

12 of 50 sites recruiting
  • Huainan First People's Hospital
    Huainan, Anhui, China
    Recruiting
    • Mei Zhang · Contact
    • Chuanqing Yu · Contact
  • Beijing Anding Hospital, Capital Medical University
    Beijing, Beijing, China
    Not yet recruiting
    • Qinge Zhang · Contact
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing, China
    Not yet recruiting
    • Guangzhi Liu · Contact
  • Beijing Hospital
    Beijing, Beijing, China
    Not yet recruiting
    • Haibo Chen · Contact
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing, China
    Not yet recruiting
    • Jiawei Wang · Contact
  • Peking University Shougang Hospital
    Beijing, Beijing, China
    Not yet recruiting
    • Shudong Qiao · Contact
  • The First Medical Center, Chinese PLA General Hospital
    Beijing, Beijing, China
    Not yet recruiting
    • Shengyuan Yu · Contact
  • Xuanwu Hospital, Capital Medical University
    Beijing, Beijing, China
    Recruiting
    • Jianping Jia · Contact
  • The First Affiliated Hopsital of Xiamen University
    Xiamen, Fujian, China
    Not yet recruiting
    • Kunmu Zheng · Contact
  • Guangdong Provincial Hospital of Chinese Medicine
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Yefeng Cai · Contact
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Yuping Ning · Contact
  • The First Affiliated Hopsital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Qin Liu · Contact
  • The Second Affiliated Hopsital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Jun Liu · Contact
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong, China
    Not yet recruiting
    • Xuhui Chen · Contact
  • The First People's Hospital of Nanning
    Nanning, Guangxi, China
    Recruiting
    • Xianfeng Li · Contact
  • Shijiazhuang People's Hospital
    Shijiazhuang, Hebei, China
    Recruiting
    • Huiying Zhao · Contact
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Qinying Ma · Contact
  • The Second Hopsital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Not yet recruiting
    • Yaling Liu · Contact
  • Tangshan Workers' Hospital
    Tangshan, Hebei, China
    Recruiting
    • Yongqiu Li · Contact
  • The First Affiliated Hopsital of Nanyang Medical College
    Nanyang, Henan, China
    Not yet recruiting
    • Qian Deng · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
    • Jiewen Zhang · Contact
  • Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)
    Wuhan, Hubei, China
    Not yet recruiting
    • Wei Shao · Contact
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Not yet recruiting
    • Deren Hou · Contact
  • Xiangya Hospital Central South University
    Changsha, Hunan, China
    Not yet recruiting
    • Lu Shen · Contact
  • Chenzhou First People's Hospital
    Chenzhou, Hunan, China
    Not yet recruiting
    • Xiaoxi Yao · Contact
  • Yueyang Central Hospital
    Yueyang, Hunan, China
    Not yet recruiting
    • Xiang Huang · Contact
  • Huai'an Second People's Hospital
    Huai'an, Jiangsu, China
    Not yet recruiting
    • Liandong Zhao · Contact
  • Nanjing Brain Hospital
    Nanjing, Jiangsu, China
    Not yet recruiting
    • Rong Lu · Contact
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
    Not yet recruiting
    • Maohong Cao · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
    Recruiting
    • Guiyun Cui · Contact
  • Yangzhou First People's Hospital
    Yangzhou, Jiangsu, China
    Not yet recruiting
    • Tieyu Tang · Contact
  • Jiujiang University Affiliated Hospital
    Jiujiang, Jiangxi, China
    Recruiting
    • Xiangbin Wu · Contact
  • The Second Affiliated Hopsital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Zhenyu Tang · Contact
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
    • Li Sun · Contact
  • Inner Mongolia International Hospital of Mongolian Medicine
    Hohhot, Neimenggu, China
    Not yet recruiting
    • Qile Temu · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Not yet recruiting
    • Yi Li · Contact
  • Shandong Provincial Hospital
    Jinan, Shandong, China
    Not yet recruiting
    • Yifeng Du · Contact
  • Qilu Hospital of Shandong University (Qingdao)
    Qingdao, Shandong, China
    Not yet recruiting
    • Chuanzhu Yan · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Not yet recruiting
    • Yanping Sun · Contact
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
    Not yet recruiting
    • Zhigang Liang · Contact
  • Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
    Not yet recruiting
    • Jianren Liu · Contact
  • The Second Affiliated Hospital of Air Force Medical University (Tangdu Hospital of Air Force Medical University)
    Xi'an, Shanxi, China
    Not yet recruiting
    • Wei Zhang · Contact
  • Xi'an Mental Health Center
    Xi'an, Shanxi, China
    Not yet recruiting
    • Wei Dang · Contact
  • Xianyang Hospital of Yan'an University
    Xianyang, Shanxi, China
    Not yet recruiting
    • Aihong Guo · Contact
  • Hospital of Chengdu University of TCM
    Chengdu, Sichuan, China
    Not yet recruiting
    • Dongdong Yang · Contact
  • Tianjin People's Hospital
    Tianjin, Tianjin, China
    Not yet recruiting
    • Meiyun Zhang · Contact
  • The Affiliated Hopsital of Inner Mongolia Medical University
    Urumqi, Xinjiang, China
    Not yet recruiting
    • Chunyang Li · Contact
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Not yet recruiting
    • Xiufeng Xu · Contact
  • The First Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Guoping Peng · Contact
  • The Second Hospital of Jiaxing
    Jiaxing, Zhejiang, China
    Recruiting
    • Yanping Wang · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jun 2029, 70 months after the start.

Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 18, 2023
StartActual
Aug 31, 2023
Primary completionEst.
Jun 2029
CompletionEst.
Dec 2029
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05908695
Lead sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Aug 31, 2023
Primary completion
Jun 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 9, 2023

Study contacts

Medical Director, Ph. D
Contact
xinxianliang@greenvalleypharma.com
+86 21 50504988 ext. 8821

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV-971

Start the discussion